安麦角 | 121588-75-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 中文名称: 安麦角
• 英文名称: amesergide
• 英文别名: (8β)-N-cyclohexyl-1-isopropyl-6-methylergoline-8-carboxamide；(6aR,9R,10aR)-N-cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
• CAS: 121588-75-8
• 化学式: C₂₅H₃₅N₃O
• 分子量: 393.572
• InChiKey: KEMOOQHMCGCZKH-JMUQELJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  安麦角 在 吡啶 、 迭氮酸 、 五氯化磷 作用下， 生成 (6aR,9R,10aR)-9-(1-cyclohexyltetrazol-5-yl)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
  参考文献：
  名称：

  (8.beta.)-6-Methylergoline amide derivatives as serotonin antagonists: N1-substituent effects on vascular 5HT2 receptor activity

  摘要：

  A series of (8 beta)-6-methylergoline amide derivatives was synthesized with various alkyl substituents in the N1-position in order to evaluate their effectiveness in blocking vascular 5HT2 receptors. The influence of both the N1 substituent and amide derivative proved to be of great importance on binding affinities to vascular 5HT2 receptors. Within each series of amides, however, maximum affinity was achieved with an N1-isopropyl substituent (14, 18, 26, 38, and 41; all with 2.7-50 times greater affinity than their N1-H analogues), with the exception of two cases (22 and 37) in the cyclohexylamide derivatives wherein N1-methyl equalled the isopropyl in potency. Other than these exceptions, affinities followed the pattern of H less than Me less than Et less than iPr, with potencies falling off with larger alkyl substituents.

  DOI：

  10.1021/jm00164a029
• 作为产物：
  描述：

  1-异丙基二氢麦角酸 、 环己胺 以76.8的产率得到安麦角
  参考文献：
  名称：

  Cycloalkylamides of (8.beta.)-1-alkyl-6-(substituted) ergolines

  摘要：

  本发明提供了(8.beta.)-N-环烷基-1-烷基-6-(取代) 艾角啉-8-羧酰胺，用于阻断中枢或外周存在过量血清素的哺乳动物的5HT.sub.2 受体。本发明还提供了使用本发明化合物治疗高血压、偏头痛、血管痉挛、血栓形成、缺血、抑郁症、焦虑症、睡眠障碍和食欲障碍的方法。

  公开号：

  US04931447A1

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Catechol protected levodopa diester prodrugs, compositions, and methods of use
  申请人：Xiang Jia-Ning

  公开号：US20080171789A1

  公开（公告）日：2008-07-17

  Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.

  提供了一种保护左旋多巴二酯前药的制药品，包括含有保护左旋多巴二酯前药的制剂，以及利用这种前药和制药组合物治疗帕金森病等疾病的方法。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Levodopa prodrug mesylate, compositions thereof, and uses thereof
  申请人：Xiang Jia-Ning

  公开号：US20070225366A1

  公开（公告）日：2007-09-27

  (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.

  提供了(2R)-2-苯甲酰氧基丙基(2S)-2-氨基-3-(3,4-二羟基苯基)丙酸甲磺酸盐及其结晶形式、制备方法、药物组合物以及利用它们治疗帕金森病等疾病或疾病的方法。